Silverarc Capital Management, Llc Buys Aclaris Therapeutics Inc, Merus NV, Research Alliance Corp II, Sells Delcath Systems Inc, Vericel Corp, Sutro Biopharma Inc

• New Purchases: ACRS, RACB, MRUS, MSACU, ALDX, VCYT, EYPT, SLRX, ONCR, CYCC, ODT, CHRS, PYPD, KALV, APTO, BLRX, TVTX, IMTX, VRDN, RXDX, RXDX, WVE, BDTX, PIRS,
• Added Positions: BHVN, HZNP, MCRB, FULC, CRIS, IMGN, AFMD, SRRK, BIIB, VRTX, MORF, INSM, TCRR, ADMS, MRSN, HALO, VSTM, HLXA, ASND, ETNB, CCXI, DCPH, LPTX, TPTX, CALA, RACA,
• Reduced Positions: DCTH, VCEL, MRTX, EPIX, ARVN, CLRB, IMVT, ITCI, COGT, EVGN, GH, CGEN, TRIL, DRNA, LRMR, ARDX, SGEN, GMDA, JNCE, SLNO, MREO, 7AY1, KURA, SURF, SNDX, OTIC, AKRO,
• Sold Out: STRO, ZYME, CLDX, NXTC, KDMN, NKTX, BCRX, ALXN, CNST, EXAS, ZNTL, IOVA, PTGX, APTX, ARQT,

For the details of SILVERARC CAPITAL MANAGEMENT, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/silverarc+capital+management%2C+llc/current-portfolio/portfolio

1. Aclaris Therapeutics Inc (ACRS) - 336,737 shares, 4.89% of the total portfolio. New Position
2. Curis Inc (CRIS) - 628,793 shares, 4.10% of the total portfolio. Shares added by 18.64%
3. Vericel Corp (VCEL) - 122,125 shares, 3.91% of the total portfolio. Shares reduced by 56.59%
4. Insmed Inc (INSM) - 190,810 shares, 3.75% of the total portfolio. Shares added by 9.03%
5. Immunogen Inc (IMGN) - 729,364 shares, 3.40% of the total portfolio. Shares added by 21.56%

Silverarc Capital Management, Llc initiated holding in Aclaris Therapeutics Inc. The purchase prices were between $5.86 and $27.73, with an estimated average price of $19.63. The stock is now traded at around $22.775000. The impact to a portfolio due to this purchase was 4.89%. The holding were 336,737 shares as of 2021-03-31.

Silverarc Capital Management, Llc initiated holding in Merus NV. The purchase prices were between $16.14 and $29.11, with an estimated average price of $23.11. The stock is now traded at around $25.185000. The impact to a portfolio due to this purchase was 2.95%. The holding were 244,713 shares as of 2021-03-31.

Silverarc Capital Management, Llc initiated holding in Research Alliance Corp II. The purchase prices were between $10.16 and $10.41, with an estimated average price of $10.24. The stock is now traded at around $10.000000. The impact to a portfolio due to this purchase was 2.95%. The holding were 500,000 shares as of 2021-03-31.

Silverarc Capital Management, Llc initiated holding in Medicus Sciences Acquisition Corp. The purchase prices were between $9.85 and $10.55, with an estimated average price of $10.15. The stock is now traded at around $10.100000. The impact to a portfolio due to this purchase was 2.31%. The holding were 406,791 shares as of 2021-03-31.

Silverarc Capital Management, Llc initiated holding in Aldeyra Therapeutics Inc. The purchase prices were between $6.53 and $14.42, with an estimated average price of $11.53. The stock is now traded at around $11.510000. The impact to a portfolio due to this purchase was 2.2%. The holding were 321,879 shares as of 2021-03-31.

Silverarc Capital Management, Llc initiated holding in Veracyte Inc. The purchase prices were between $44.47 and $81.38, with an estimated average price of $57.89. The stock is now traded at around $36.350000. The impact to a portfolio due to this purchase was 1.86%. The holding were 60,000 shares as of 2021-03-31.

Silverarc Capital Management, Llc added to a holding in Biohaven Pharmaceutical Holding Co Ltd by 203.57%. The purchase prices were between $64.07 and $91.75, with an estimated average price of $80.92. The stock is now traded at around $71.900000. The impact to a portfolio due to this purchase was 1.32%. The holding were 50,089 shares as of 2021-03-31.

Silverarc Capital Management, Llc added to a holding in Horizon Therapeutics PLC by 61.59%. The purchase prices were between $71.83 and $95.48, with an estimated average price of $84.49. The stock is now traded at around $91.300000. The impact to a portfolio due to this purchase was 0.98%. The holding were 48,476 shares as of 2021-03-31.

Silverarc Capital Management, Llc added to a holding in Seres Therapeutics Inc by 300.00%. The purchase prices were between $17.66 and $28.92, with an estimated average price of $23.07. The stock is now traded at around $21.820000. The impact to a portfolio due to this purchase was 0.89%. The holding were 100,000 shares as of 2021-03-31.

Silverarc Capital Management, Llc added to a holding in Fulcrum Therapeutics Inc by 648.36%. The purchase prices were between $10.94 and $15.32, with an estimated average price of $12.39. The stock is now traded at around $9.770000. The impact to a portfolio due to this purchase was 0.71%. The holding were 121,302 shares as of 2021-03-31.

Silverarc Capital Management, Llc added to a holding in Immunogen Inc by 21.56%. The purchase prices were between $6.5 and $10.53, with an estimated average price of $8.2. The stock is now traded at around $6.600000. The impact to a portfolio due to this purchase was 0.6%. The holding were 729,364 shares as of 2021-03-31.

Silverarc Capital Management, Llc added to a holding in Affimed NV by 25.58%. The purchase prices were between $5.12 and $8.48, with an estimated average price of $6.49. The stock is now traded at around $9.460000. The impact to a portfolio due to this purchase was 0.47%. The holding were 502,330 shares as of 2021-03-31.

Silverarc Capital Management, Llc sold out a holding in Sutro Biopharma Inc. The sale prices were between $20.29 and $27.54, with an estimated average price of $23.73.

Silverarc Capital Management, Llc sold out a holding in Zymeworks Inc. The sale prices were between $29.83 and $56.81, with an estimated average price of $40.65.

Silverarc Capital Management, Llc sold out a holding in Celldex Therapeutics Inc. The sale prices were between $16.19 and $29.91, with an estimated average price of $22.98.

Silverarc Capital Management, Llc sold out a holding in NextCure Inc. The sale prices were between $9.81 and $13.88, with an estimated average price of $12.09.

Silverarc Capital Management, Llc sold out a holding in Kadmon Holdings Inc. The sale prices were between $3.58 and $5.51, with an estimated average price of $4.58.

Silverarc Capital Management, Llc sold out a holding in Nkarta Inc. The sale prices were between $31.33 and $59.61, with an estimated average price of $47.87.